Clinical trials
Completed Fanconi Anemia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 6 |
| 2001 | 1 |
| 2002 | 3 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 36 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital Medical Center, Cincinnati | 6 |
| University of California, San Francisco | 5 |
| Fred Hutchinson Cancer Center | 3 |
| Masonic Cancer Center, University of Minnesota | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| Boston Children's Hospital | 2 |
| Fairview University Medical Center | 2 |
| OHSU Knight Cancer Institute | 2 |
| Roswell Park Cancer Institute | 2 |
| Children's Oncology Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fanconi Anemia | 36 |
| Anemia, Aplastic | 6 |
| Anemia, Sickle Cell | 5 |
| Hematologic Neoplasms | 5 |
| Anemia, Diamond-Blackfan | 4 |
| Hematologic Diseases | 4 |
| Hemoglobinopathies | 4 |
| Immunologic Deficiency Syndromes | 4 |
| Thalassemia | 4 |
| Congenital Abnormalities | 3 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.